Treating Life-Threatening Myocarditis by Blocking Interleukin-1

Area of Science:

• Cardiology
• Immunology
• Critical Care Medicine

Background:

• Fulminant myocarditis treatment often requires intensive life support.
• Interleukin-1 (IL-1) plays a role in myocardial inflammation and dysfunction.
• Targeting IL-1 may offer a novel therapeutic strategy for inflammatory heart conditions.

Observation:

• A 36-year-old female presented with fulminant myocarditis, biventricular failure, and cardiogenic shock.
• Despite extracorporeal membrane oxygenation and mechanical circulatory support, her cardiac function deteriorated.
• Treatment with anakinra, an IL-1 receptor antagonist, was initiated.

Findings:

• Anakinra treatment led to prompt improvement in severe cardiac dysfunction.
• Within four days, the patient was weaned from mechanical support and discharged.
• The patient maintained excellent health at 12-month follow-up.

Implications:

• IL-1 blockade demonstrates efficacy in reducing myocardial inflammation and improving contractile function.
• Anakinra presents a promising therapeutic option for inflammatory heart failure.
• These findings suggest anakinra could be a viable treatment for fulminant myocarditis, warranting further investigation.